Epstein–Barr virus (Orthoherpesviridae: Lymphocryptovirus) among Russian ethnic groups: Prevalence of EBV types (EBV-1 and EBV-2), LMP1 gene variants and malignancies

封面图片

如何引用文章

全文:

详细

Introduction. The discovery of two EBV types (EBV-1 and EBV-2) has stimulated the study of their prevalence in populations and association with malignancies.

Objective. To study the prevalence of EBV-1 and EBV-2 types among ethnic groups in Russia, to analyze PCR products of the LMP1 gene in virus isolates, and to evaluate the contribution of EBV types to the incidence of malignant neoplasms.

Materials and methods. EBV isolates from oral lavages of the Republics Adygea, Kalmykia, Tatarstan and the Moscow Region (MR) representatives were studied by nested PCR for the belonging to EBV-1 and EBV-2 types. LMP1 amplicons obtained by real-time PCR from viral isolates DNA were classified and sequenced on an automatic DNA sequencer ABI PRISM 3100-Avant (USA). The sequencing results were analyzed using Chromas 230 and Vector NT programs (Invitrogen, USA). The reliability of the obtained data was assessed using statistical packages Statistica for Windows, 10.0.

Results. The prevalence rates of EBV-1 and EBV-2 in representatives of four ethnic groups were compared with the incidence rates of some tumors in the population of three Republics and MR.

The dominant persistence of the transforming in vitro EBV-1 type in representatives of the Republic of Tatarstan and MR correlated with a high incidence of gastric cancer and lymphomas in the population of these territories. On the contrary, predominant infection of the non-transforming in vitro EBV-2 type and both types of the virus in approximately the same percentage of representatives of Adygea and Kalmykia, respectively, correlated with a lower level incidence of above tumors in populations of these Republics. The differences between the incidence rates of neoplasms in the compared ethnic populations were statistically insignificant (p > 0.05). LMP1 variants of viral isolates did not reflect either the level of EBV persistence types or the incidence of tumors.

Conclusion. Infection of ethnic groups with EBV-1 and EBV-2 may vary significantly under the influence of various factors. The predominance of the in vitro transforming EBV-1 type in the population did not increase the incidence of tumors due to cases associated with the dominant virus type.

作者简介

Vladimir Gurtsevitch

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

编辑信件的主要联系方式.
Email: gurtsevitch-vlad-88@yandex.ru
ORCID iD: 0000-0003-1840-4364

Dr. Sci. (Medicine), Professor, Chief Scientific Adviser of the Laboratory of Viral Carcinogenesis, Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

俄罗斯联邦, 115478, Moscow

Alexandra Lubenskaya

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: lubenskoy.96@mail.ru
ORCID iD: 0000-0003-3953-7449

Researcher, Laboratory of Viral Carcinogenesis, Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

俄罗斯联邦, 115478, Moscow

Natalia Senyuta

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: nat.senyuta@yandex.ru
ORCID iD: 0000-0001-8915-8274

PhD (Medicine), Scientific Consultant of the Laboratory of Viral Carcinogenesis, Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

俄罗斯联邦, 115478, Moscow

Ksenia Smirnova

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; The Peoples’ Friendship University of Russia (RUDN University); Pirogov Russian National Research Medical University (Pirogov Medical University)

Email: skv.lab@yandex.ru
ORCID iD: 0000-0001-6209-977X

PhD (Biology), Head of the Laboratory of Viral Carcinogenesis, Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, RUDN University, Pirogov Medical University

俄罗斯联邦, 115478, Moscow; 117998, Moscow; 117997, Moscow

参考

  1. Shannon-Lowe C., Rickinson A. The global landscape of EBV-associated tumors. Front. Oncol. 2019; 9: 713. https://doi.org/10.3389/fonc.2019.00713
  2. Graham B.S., Lynch D.T. Burkitt Lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
  3. Tsao S.W., Tsang C.M., Lo K.W. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2017; 372(1732): 20160270. https://doi.org/10.1098/rstb.2016.0270
  4. Bei J.X., Zuo X.Y., Liu W.S., Guo Y.M., Zeng Y.X. Genetic susceptibility to the endemic form of NPC. Chin. Clin. Oncol. 2016; 5(2): 15. https://doi.org/10.21037/cco.2016.03.11
  5. Su W.H., Hildesheim A., Chang Y.S. Human leukocyte antigens and Epstein–Barr virus-associated nasopharyngeal carcinoma: old associations offer new clues into the role of immunity in infection-associated cancers. Front. Oncol. 2013; 3: 299. https://doi.org/10.3389/fonc.2013.00299
  6. Rickinson A.B., Young L.S., Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J. Virol. 1987; 61(5): 1310–7. https://doi.org/10.1128/jvi.61.5.1310-1317.1987
  7. Romero-Masters J.C., Huebner S.M., Ohashi M., Bristol J.A., Benner B.E., Barlow E.A., et al. B cells infected with Type 2 Epstein–Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection. PLoS Pathog. 2020; 16(2): e1008365. https://doi.org/10.1371/journal.ppat.1008365
  8. Correa R.M., Fellner M.D., Alonio L.V., Durand K., Teyssié A.R., Picconi M.A. Epstein–Barr virus (EBV) in healthy carriers: Distribution of genotypes and 30 bp deletion in latent membrane protein-1 (LMP-1) oncogene. J. Med. Virol. 2004; 73(4): 583–8. https://doi.org/10.1002/jmv.20129
  9. Srivastava G., Wong K.Y., Chiang A.K., Lam K.Y., Tao Q. Coinfection of multiple strains of Epstein–Barr virus in immunocompetent normal individuals: reassessment of the viral carrier state. Blood. 2000; 95(7): 2443–5.
  10. Van Baarle D., Hovenkamp E., Kersten M.J., Klein M.R., Miedema F., van Oers M.H. Direct Epstein–Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma. Blood. 1999; 93(11): 3949–55.
  11. Sixbey J.W., Shirley P., Chesney P.J., Buntin D.M., Resnick L. Detection of a second widespread strain of Epstein–Barr virus. Lancet. 1989; 2(8666): 761–5. https://doi.org/10.1016/s0140-6736(89)90829-5
  12. Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein–Barr virus strains. Virology. 1999; 261(1): 79–95. https://doi.org/10.1006/viro.1999.9855
  13. Cheung S.T., Leung S.F., Lo K.W., Chiu K.W., Tam J.S., Fok T.F., et al. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. Int. J. Cancer. 1998; 76(3): 399–406. https://doi.org/10.1002/(sici)1097-0215(19980504)76:3<399:aid-ijc18>3.0.co;2-6
  14. Oshima M., Azuma H., Okuno A. High prevalence of Epstein-Barr virus type A strain with the 30 b.p. deletion of the latent membrane protein-1 gene in a Japanese population. Pediatr. Int. 1999; 41(5): 490–5. https://doi.org/10.1046/j.1442-200x.1999.01122.x
  15. Khanim F., Yao Q.Y., Niedobitek G., Sihota S., Rickinson A.B., Young L.S. Analysis of Epstein–Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood. 1996; 88(9): 3491–501.
  16. Smirnova K.V., Senyuta N.B., Botezatu I.V., Dushen’kina T.E., Lubenskaya A.K., Frolovskaya A.A., et al. Epstein–Barr virus in the ethnic Tatars population: the infection and sequence variants of LMP1 oncogene. Uspekhi molekulyarnoy onkologii. 2018; 5(3): 65–74. https://doi.org/10.17650/2313-805X-2018-5-3 https://elibrary.ru/vloxpu (in Russian)
  17. Hahn P., Novikova E., Scherback L., Janik C., Pavlish O., Arkhipov V., et al. The LMP1 gene isolated from Russian nasopharyngeal carcinoma has no 30-bp deletion. Int. J. Cancer. 2001; 91(6): 815–21. https://doi.org/10.1002/1097-0215(200002)9999:9999<::aid-ijc1122>3.0.co;2-w
  18. Hassan R., White L.R., Stefanoff C.G., de Oliveira D.E., Felisbino F.E., Klumb C.E., et al. Epstein–Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt’s lymphoma. Diagn. Pathol. 2006; 1: 17. https://doi.org/10.1186/1746-1596-1-17
  19. Salahuddin S., Khan J., Azhar J., B. Whitehurst C., Qadri I., Shackelford J., et al. Prevalence of Epstein–Barr Virus Genotypes in Pakistani Lymphoma Patients. Asian Pac. J. Cancer Prev. 2018; 19(11): 3153–9. https://doi.org/10.31557/APJCP.2018.19.11.3153
  20. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O., eds. Malignant Neoplasms in Russia in 2020 (Morbidity and Mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2020 godu (zabolevaemost’ i smertnost’)]. Moscow; 2021. (in Russian)
  21. Young L.S., Yao Q.Y., Rooney C.M., Sculley T.B., Moss D.J., Rupani H., et al. New type B isolates of Epstein–Barr virus from Burkitt’s lymphoma and from normal individuals in endemic areas. J. Gen. Virol. 1987; 68(Pt. 11): 2853–62. https://doi.org/10.1099/0022-1317-68-11-2853

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. The ratio of EBV-1 and EBV-2 in oral lavages of four ethnic groups’ representatives: Adygeans, Kalmyks, Tatars and Slavs.

下载 (375KB)
索引源数据
3. Fig. 2. Incidence rates of malignant neoplasms with EBV-associated cases among the population of the Republics of Adygea, Kalmykia, Tatarstan and the Moscow region.

下载 (547KB)
索引源数据

版权所有 © Gurtsevitch V.E., Lubenskaya A.K., Senyuta N.B., Smirnova K.V., 2024

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##